214 related articles for article (PubMed ID: 12958701)
1. Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.
Richardson SK; McGinnis KS; Shapiro M; Lehrer MS; Kim EJ; Vittorio CC; Junkins Hopkins JM; Rook AH
J Cutan Med Surg; 2003; 7(4 Suppl):8-12. PubMed ID: 12958701
[No Abstract] [Full Text] [Related]
2. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma.
Duvic M; Chiao N; Talpur R
J Cutan Med Surg; 2003; 7(4 Suppl):3-7. PubMed ID: 12958700
[No Abstract] [Full Text] [Related]
3. Optimal combination with PUVA: rationale and clinical trial update.
Stadler R
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):29-32. PubMed ID: 17474357
[TBL] [Abstract][Full Text] [Related]
4. Management of cutaneous T-cell lymphoma: The future is here.
Wood GS
J Am Acad Dermatol; 2001 Aug; 45(2):317. PubMed ID: 11464201
[No Abstract] [Full Text] [Related]
5. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome.
McGinnis KS; Ubriani R; Newton S; Junkins-Hopkins JM; Vittorio CC; Kim EJ; Wysocka M; Rook AH
Arch Dermatol; 2005 Sep; 141(9):1176-8. PubMed ID: 16172331
[No Abstract] [Full Text] [Related]
6. [Cutaneous T-cell lymphoma].
Dippel E; Gellrich S; Klemke CD; Goerdt S; Sterry W
J Dtsch Dermatol Ges; 2003 Dec; 1(12):965-80; quiz 981-2. PubMed ID: 16285650
[No Abstract] [Full Text] [Related]
7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
8. High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome.
Richardson SK; Lin JH; Vittorio CC; Kim EJ; Yoon JS; Junkins-Hopkins J; Rook AH
Clin Lymphoma Myeloma; 2006 Nov; 7(3):226-32. PubMed ID: 17229339
[TBL] [Abstract][Full Text] [Related]
9. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Whitmore SE
J Am Acad Dermatol; 2004 Sep; 51(3):482; author reply 482-3. PubMed ID: 15338005
[No Abstract] [Full Text] [Related]
10. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
Siakantaris MP; Tsirigotis P; Stavroyianni N; Argyropoulos KV; Girkas K; Pappa V; Chondropoulos S; Papadavid E; Sakellari I; Anagnostopoulos A; Antoniou C; Dervenoulas J
Transfus Apher Sci; 2012 Apr; 46(2):189-93. PubMed ID: 22178592
[TBL] [Abstract][Full Text] [Related]
11. Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis.
Durgin JS; Jariwala NN; Wysocka M; Zhang KK; Maity A; Benoit B; Plastaras JP; Lewis DJ; Rosenthal JM; Teague JE; Berg S; Del Guzzo C; Kim EJ; Vittorio C; Haun PL; Samimi SS; Villasenor-Park J; Inverso J; Clark RA; Rook AH
JAMA Dermatol; 2021 Jan; 157(1):90-95. PubMed ID: 33112366
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure.
Bagot M
Dermatol Clin; 2008 Jan; 26 Suppl 1():27-9. PubMed ID: 18405184
[No Abstract] [Full Text] [Related]
13. Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma.
Dippel E; Schrag H; Goerdt S; Orfanos CE
Lancet; 1997 Jul; 350(9070):32-3. PubMed ID: 9217723
[No Abstract] [Full Text] [Related]
14. Proceedings of the Second International Symposium on Cutaneous T-cell Lymphoma. Chicago, Illinois, Oct. 13-17, 1993.
Herrmann JJ; Kuzel TM; Rosen ST; Roenigk HH
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):819-22. PubMed ID: 7523465
[No Abstract] [Full Text] [Related]
15. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.
Shapiro M; Rook AH; Lehrer MS; Junkins-Hopkins JM; French LE; Vittorio CC
J Am Acad Dermatol; 2002 Dec; 47(6):956-61. PubMed ID: 12451388
[No Abstract] [Full Text] [Related]
16. Evidence is lacking for a synergistic or additive effect of combination extracorporeal photopheresis with interferon alfa for cutaneous T-cell lymphoma.
Zackheim HS
J Am Acad Dermatol; 2000 Jun; 42(6):1087-8. PubMed ID: 10827420
[No Abstract] [Full Text] [Related]
17. Management of the primary cutaneous lymphomas.
Prince HM; McCormack C; Ryan G; O'Keefe R; Seymour JF; Baker C
Australas J Dermatol; 2003 Nov; 44(4):227-40; quiz 241-2. PubMed ID: 14616487
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
Ferenczi K; Yawalkar N; Jones D; Kupper TS
Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome.
Fritz TM; Kleinhans M; Nestle FO; Burg G; Dummer R
Br J Dermatol; 1999 Jun; 140(6):1144-7. PubMed ID: 10354086
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic advances in biological response modifiers in the treatment of cutaneous T-cell lymphoma.
Vittorio CC; Rook AH; French LE; Shapiro M; Lehrer MS; Junkins-Hopkins JM
BioDrugs; 2001; 15(7):431-7. PubMed ID: 11520254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]